The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors

被引:1
作者
Si, Han [1 ,2 ]
Fu, Xiaoshuang [1 ,2 ]
Hao, Yue [2 ]
Wang, Yina [3 ]
Lin, Gen [4 ,5 ]
Wang, Dong [6 ]
Xu, Chunwei [7 ]
Zhang, Yongchang [8 ]
Song, Zhongbo [1 ,2 ]
机构
[1] Wenzhou Med Univ, Zhejiang Canc Hosp, Postgrad Training Base Alliance, Hangzhou, Peoples R China
[2] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Clin Trial, 1 East Banshan Rd, Hangzhou 310022, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Oncol, Hangzhou 310000, Peoples R China
[4] Fujian Med Univ Canc Hosp, Dept Med Oncol, Fuzhou 350014, Peoples R China
[5] Fujian Canc Hosp, Fuzhou 350014, Peoples R China
[6] Nanjing Univ, Jinling Hosp, Sch Med, Dept Resp & Crit Care Med, Nanjing 210000, Peoples R China
[7] Chinese Acad Sci, Hangzhou Inst Med HIM, Hangzhou 310022, Zhejiang, Peoples R China
[8] Cent South Univ, Hunan Canc Hosp, Lung Canc & Gastrointestinal Unit, Dept Med Oncol,Affiliated Canc Hosp,Xiangya Sch Me, Changsha 410013, Peoples R China
关键词
PD-L1; Combination therapy; Targeted therapy; Efficacy; IMMUNE CHECKPOINT INHIBITORS; CANCER;
D O I
10.1007/s12094-024-03618-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe significant expression of PD-L1 in thymic epithelial tumors (TETs) has been confirmed, and immunotherapy and its combination therapy have been effective in TETs. However, there is no present evidence that the expression levels of PD-L1 affects the efficacy of combination therapy. Our study aimed to shed light on this relationship.MethodsPatients with thymic epithelial tumors (TETs) from multicenter hospitals were retrospectively identified. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAEs) in 22 patients were included. We divided the patients the 22 patients with PD-L1 test into three levels (high expression, low expression and no expression) and analyzed the relationship between the levels of PD-L1 expression and the efficacy of combination therapy.ResultsCombination therapy showed an effective benefit in 22 patients with TETs, the median PFS (mPFS) was 16 months (95% CI: 8.5-23.5) and the median OS (mOS) was 38 months (95% CI: 21.5-54.5). Cox-regressive analysis found whether PD-L1 expression affected the PFS of patients (p = 0.017). Among the patients with PD-L1 expression, the levels of expression were correlated with curative effect (Kruskal-Wallis test, PFS: P = 0.012; OS: P = 0.01), and high expression group was along with better efficacy than low expression (Wilcoxon test, P = 0.01). Moreover, in 17 patients treated with immunotherapy combined with chemotherapy, the expression of PD-L1 was also associated with efficacy (Kruskal-Wallis test, p = 0.021).ConclusionsPD-L1 expression affects the PFS of patients. High expression of PD-L1 patients with TETs responded better to combination therapy, which could provide a therapeutic option in clinic. Besides, other targeted treatments should be considered.
引用
收藏
页码:542 / 548
页数:7
相关论文
共 34 条
[1]   PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors [J].
Alberobello, Anna Teresa ;
Wang, Yisong ;
Beerkens, Frans Joseph ;
Conforti, Fabio ;
McCutcheon, Justine N. ;
Rao, Guanhua ;
Raffeld, Mark ;
Liu, Jing ;
Rahhal, Raneen ;
Zhang, Yu-Wen ;
Giaccone, Giuseppe .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) :1345-1356
[2]   Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives [J].
Ao, Yong-Qiang ;
Gao, Jian ;
Wang, Shuai ;
Jiang, Jia-Hao ;
Deng, Jie ;
Wang, Hai-Kun ;
Xu, Bei ;
Ding, Jian-Yong .
MOLECULAR CANCER, 2023, 22 (01)
[3]   PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus [J].
Bagir, Emine Kilic ;
Acikalin, Arbil ;
Avci, Alper ;
Gumurdulu, Derya ;
Paydas, Semra .
JOURNAL OF CLINICAL PATHOLOGY, 2018, 71 (07) :637-641
[4]   Thymic Epithelial Neoplasms Tumor-Node-Metastasis Staging [J].
Benveniste, Marcelo F. K. ;
Cuellar, Sonia L. Betancourt ;
Carter, Brett W. ;
Strange, Chad D. ;
Marom, Edith M. .
RADIOLOGIC CLINICS OF NORTH AMERICA, 2021, 59 (02) :183-192
[5]   Heat Shock Protein 90-Sheltered Overexpression of Insulin-Like Growth Factor 1 Receptor Contributes to Malignancy of Thymic Epithelial Tumors [J].
Breinig, Marco ;
Mayer, Philipp ;
Harjung, Andreas ;
Goeppert, Benjamin ;
Malz, Mona ;
Penzel, Roland ;
Neumann, Olaf ;
Hartmann, Arndt ;
Dienemann, Hendrik ;
Giaccone, Giuseppe ;
Schirmacher, Peter ;
Kern, Michael Andre ;
Chiosis, Gabriela ;
Rieker, Ralf Joachim .
CLINICAL CANCER RESEARCH, 2011, 17 (08) :2237-2249
[6]   Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine [J].
Chen, Vincent ;
Umemura, Shigeki ;
Han, Yumin ;
Raman, Renuka ;
Tucker, Robin ;
Chahine, Joeffrey ;
Kim, In-Kyu ;
Schatz, Christoph ;
Zitzmann-Kolbe, Sabine ;
Sommer, Anette ;
Onda, Masanori ;
Lee, Trevor ;
He, Yongfeng ;
Giaccone, Giuseppe .
BRITISH JOURNAL OF CANCER, 2022, 126 (05) :754-763
[7]   Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management [J].
Colli, Leandro M. ;
Machiela, Mitchell J. ;
Zhang, Han ;
Myers, Timothy A. ;
Jessop, Lea ;
Delattre, Olivier ;
Yu, Kai ;
Chanock, Stephen J. .
CANCER RESEARCH, 2017, 77 (13) :3666-3671
[8]   Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials [J].
Conforti, Fabio ;
Pala, Laura ;
De Pas, Tommaso ;
He, Yongfeng ;
Giaccone, Giuseppe .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (09) :895-904
[9]   Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort [J].
du Vignaux, Claire Merveilleux ;
Dansin, Eric ;
Mhanna, Laurent ;
Greillier, Laurent ;
Pichon, Eric ;
Kerjouan, Mallorie ;
Clement-Duchene, Christelle ;
Mennecier, Bertrand ;
Westeel, Virginie ;
Robert, Marie ;
Quantin, Xavier ;
Zalcman, Gerard ;
Thiberville, Luc ;
Lena, Herve ;
Molina, Thierry ;
Calcagno, Fabien ;
Fournel, Pierre ;
Mazieres, Julien ;
Besse, Benjamin ;
Girard, Nicolas .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) :1762-1770
[10]   Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours [J].
Dumoulin, Daphne W. ;
Bironzo, Paolo ;
Passiglia, Francesco ;
V. Scagliotti, Giorgio ;
Aerts, Joachim G. J. V. .
EUROPEAN RESPIRATORY REVIEW, 2023, 32 (167)